Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA... by Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi

Subjects: Get full text

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists by Hirotaka Watada

Subjects: Get full text

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis by Saixian Shi, Xiaofeng Li, Ye Chen, Jiahao Li, Yan Dai

Subjects: Get full text

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence... by Jian‐Yu Jhu, Yu‐Wei Fang, Chung‐Yen Huang, Hung‐Hsiang Liou, Mon‐Ting Chen, Ming‐Hsien Tsai

Subjects: “…Glucagon‐like peptide‐1 receptor agonists…”
Get full text

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review by Yao Wang, Jiangling Wang, Qian Gong, Haoming Wu, Shuhao Yang, Jufeng He, Xulin Hu, Tianfang Huang

Subjects: “…glucagon-like peptide-1 receptor agonists (glp-1ras)…”
Get full text

Adverse effects of GLP – 1 Receptor Agonists by Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska

Subjects: “…obesity, glucagon – like peptide – 1 receptor agonists…”
Get full text